A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients who are currently on metformin monotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ConjuChem
• Treatments: Metformin

Criteria

Major Inclusion Criteria:

• BMI: 27 to 45 kg/m2

• Stable Type 2 diabetes mellitus for at least 3 months, as defined by the Investigator

• Stable life-style, i.e. diet & physical activity, as determined by the Investigator

• Stable metformin daily dose ≥1000 mg for at least 3 months

• Glycosylated hemoglobin (HbA1c) at screening ≥ 7.1% and ≤ 11%